The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.
   PubMed Web of Science ®Google Scholar
• Marston NA, Kamanu FK, Nordio F, et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the Fourier trial. Circulation. 2020;141(8):616–623.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172–1180.
   PubMed Web of Science ®Google Scholar
• Cecha P, Chromik A, Piotrowska I, Zabojszcz M, Dolecka-ślusarczyk M, Siudak Z. Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice - one center study. Folia Med Cracov. 2021;61(3):43–54.
   PubMedGoogle Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Tsui L, Ye P, Xu S, et al. Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis. Eur j Hospital Pharm. 2022;1:56.
   Google Scholar
• Lin JL, Chen PS, Lin HW, Tsai LM, Lin SH, Li YH. Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: an Asian Population-Based Study. J Atheroscler Thromb. 2022;29(8):1213–1225.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Kim DH, Burton JR, Fu Y, Lindholm L, Van de Werf F, Armstrong PW. What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? Am Heart J. 2006;151(3):668–673.
   PubMed Web of Science ®Google Scholar
• Shiono Y, Kuramitsu S, Matsuo H, et al. Thrombotic risk and cardiovascular events in patients with revascularization deferral after fractional flow reserve assessment. JACC Cardiovasc Interv. 2022;15(4):427–439.
   PubMed Web of Science ®Google Scholar
• Griffin WF, Choi AD, Riess JS, et al. AI Evaluation of Stenosis on Coronary CT Angiography, Comparison With Quantitative Coronary Angiography and Fractional Flow Reserve: a CREDENCE Trial Substudy. JACC Cardiovasc Imaging. 2022:64.
   Web of Science ®Google Scholar
• Li L, Liu QW, Li Z, et al. The utility of high-sensitivity C-reactive protein levels in patients with moderate coronary lesions and gray-zone fractional flow reserve. Anatolian j Cardiol. 2018;20(3):143–151.
   Web of Science ®Google Scholar
• Soysal D, Karakuş V, Yavaş HH, Biçeroğlu S, Köseoğlu M, Yeşil M. C-reactive protein in unstable angina pectoris and its relation to coronary angiographic severity and diffusion scores of coronary lesions. Anatolian j Cardiol. 2010;10(5):421–428.
   Web of Science ®Google Scholar
• Tu S, Westra J, Yang J, et al. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: the International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016;9(19):2024–2035.
   PubMed Web of Science ®Google Scholar
• Tesche C, De Cecco CN, Baumann S, et al. Coronary CT Angiography-derived Fractional Flow Reserve: machine Learning Algorithm versus Computational Fluid Dynamics Modeling. Radiology. 2018;288(1):64–72.
   PubMed Web of Science ®Google Scholar
• Coenen A, Kim YH, Kruk M, et al. Diagnostic Accuracy of a Machine-Learning Approach to Coronary Computed Tomographic Angiography-Based Fractional Flow Reserve: result From the MACHINE Consortium. Circ Cardiovasc Imaging. 2018;11(6):e007217.
   PubMed Web of Science ®Google Scholar
• Hwang D, Choi KH, Lee JM, et al. Diagnostic agreement of quantitative flow ratio with fractional flow reserve and instantaneous wave-free ratio. J Am Heart Assoc. 2019;8(8):e011605.
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Zhou YJ, Zhao YX, et al. Diagnostic accuracy of a deep learning approach to calculate FFR from coronary CT angiography. J Geriatr Cardiol. 2019;16(1):42–48.
   PubMedGoogle Scholar
• Brandt V, Bekeredjian R, Schoepf UJ, et al. Prognostic value of epicardial adipose tissue volume in combination with coronary plaque and flow assessment for the prediction of major adverse cardiac events. Eur J Radiol. 2022;148:110157.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang Y, Pohl K, Syeda-Mahmood T, Song Z, Wong ST. Coronary artery segmentation using geometric moments based tracking and snake-driven refinement. Ann International Conf IEEE Eng Med Biol IEEE Eng Med Biol Society Ann Int Conf. 2010;2010:3133–3137.
   PubMedGoogle Scholar
• Shah R, Clare RM, Chiswell K, et al. Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). Am J Med. 2016;129(12):1307–1315.
   PubMed Web of Science ®Google Scholar
• Danad I, Szymonifka J, Twisk JWR, et al. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J. 2017;38(13):991–998.
   PubMed Web of Science ®Google Scholar
• Piątek Ł, Janion-Sadowska A, Piątek K, et al. Long-term clinical outcomes in patients with unstable angina undergoing percutaneous coronary interventions in a contemporary registry data from Poland. Coron Artery Dis. 2020;31(3):215–221.
   PubMed Web of Science ®Google Scholar
• Strähl M, Schindler M, Keller LS, et al. Diagnostic performance of angiography-based quantitative flow ratio for the identification of myocardial ischemia as assessed by (13) N-ammoniamyocardial perfusion imaging positron emission tomography. Int J Cardiol. 2020;314:13–19.
   PubMed Web of Science ®Google Scholar
• Ray KK, Del Prato S, Müller-Wieland D, et al. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovasc Diabetol. 2019;18(1):149.
   PubMed Web of Science ®Google Scholar
• Hussain A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD Risk Reduction: recent Insights and Future Directions. Curr Atheroscler Rep. 2020;22(7):25.
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–1701.
   PubMed Web of Science ®Google Scholar
• Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155–165.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Tokgözoğlu L, Corsini A, Sirtori CR. PCSK9 inhibition and inflammation: a narrative review. Atherosclerosis. 2019;288:146–155.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018;72(3):314–329.
   PubMed Web of Science ®Google Scholar
• Tombling BJ, Zhang Y, Huang YH, Craik DJ, Wang CK. The emerging landscape of peptide-based inhibitors of PCSK9. Atherosclerosis. 2021;330:52–60.
   PubMed Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled Phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–2548.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: analysis From Fourier. Circulation. 2018;138(8):756–766.
   PubMed Web of Science ®Google Scholar
• Yano H, Horinaka S, Ishimitsu T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J Cardiol. 2020;75(3):289–295.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol. 2018;72(17):2012–2021.
   PubMed Web of Science ®Google Scholar
• Choi SW, Kim J, Jang GW, et al. Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease. J Cardiovascular Dev Dis. 2022;9:4.
   Web of Science ®Google Scholar
• Stiekema LCA, Stroes ESG, Verweij SL, et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J. 2019;40(33):2775–2781.
   PubMed Web of Science ®Google Scholar
• Ou Z, Yu Z, Liang B, et al. Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: a pilot study on Chinese patients. Front Cardiovascular Med. 2022;9:939791.
   PubMed Web of Science ®Google Scholar
• Wang X, Wen D, Chen Y, Ma L, You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis. Cardiovasc Diabetol. 2022;21(1):107.
   PubMed Web of Science ®Google Scholar
• Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019;18(7):611–621.
   PubMed Web of Science ®Google Scholar
• Nanna MG, Navar AM, Zakroysky P, et al. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA cardiol. 2018;3(8):739–748.
   PubMed Web of Science ®Google Scholar
• Joint committee issued Chinese guideline for the management of dyslipidemia in adults. 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南 (2016年修订版) [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(10):833–853. Chinese.
   PubMedGoogle Scholar
• Wei Y, Guo H, The E, et al. Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China. Int J Cardiol. 2015;182:469–475.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the Fourier trial. Lancet. 2017;390(10106):1962–1971.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: insights From the Fourier Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338–350.
   PubMed Web of Science ®Google Scholar